Press Release - Piramal Pharma Solutions ("PPS") and NewAmsterdam Pharma invest indedicated suite to enhance Oral Solid Dosage capabilities at PPS' Sellersville, Pennsylvania site
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma Solutions (PPS), the CDMO arm of Piramal Pharma, along with NewAmsterdam Pharma, has opened a dedicated oral solid dosage (OSD) manufacturing suite at the Sellersville, Pennsylvania facility. The suite is built through a multi-million-dollar investment in equipment upgrades and reconfiguration of existing space to produce a fixed-dose combination (FDC) of NewAmsterdam's investigational cholesterol drug obicetrapib with ezetimibe. The Sellersville site will handle commercial production, while Piramal's Ahmedabad site supported development and Pithampur provides dual sourcing. The investment is expected to create over 20 new jobs at Sellersville over the next five years and strengthens PPS's position as an integrated CDMO partner for global pharma clients.
This is a positive operational update for shareholders, signaling PPS's growing role as a preferred CDMO partner and expected incremental revenue from NewAmsterdam's FDC if the drug is approved. The investment size is described only as 'multi-million-dollar' with no specific figure, so the financial impact is limited at this stage.